Search results for "TUMORS"

showing 10 items of 1138 documents

Accelerated T2-Weighted TSE Imaging of the Prostate Using Deep Learning Image Reconstruction: A Prospective Comparison with Standard T2-Weighted TSE …

2021

Multiparametric MRI (mpMRI) of the prostate has become the standard of care in prostate cancer evaluation. Recently, deep learning image reconstruction (DLR) methods have been introduced with promising results regarding scan acceleration. Therefore, the aim of this study was to investigate the impact of deep learning image reconstruction (DLR) in a shortened acquisition process of T2-weighted TSE imaging, regarding the image quality and diagnostic confidence, as well as PI-RADS and T2 scoring, as compared to standard T2 TSE imaging. Sixty patients undergoing 3T mpMRI for the evaluation of prostate cancer were prospectively enrolled in this institutional review board-approved study between O…

Cancer Researchdiagnostic imagingImage qualityIterative reconstructionArticleprostatic neoplasms030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineProstateMedical imagingmedicineRC254-282Multiparametric Magnetic Resonance Imagingbusiness.industryDeep learningNeoplasms. Tumors. Oncology. Including cancer and carcinogensdeep learningmultiparametric magnetic resonance imagingmedicine.diseasemedicine.anatomical_structureOncology030220 oncology & carcinogenesisArtificial intelligenceNuclear medicinebusinessT2 weightedCancers
researchProduct

Ethanol-Mediated Stress Promotes Autophagic Survival and Aggressiveness of Colon Cancer Cells via Activation of Nrf2/HO-1 Pathway

2019

Epidemiological studies suggest that chronic alcohol consumption is a lifestyle risk factor strongly associated with colorectal cancer development and progression. The aim of the present study was to examine the effect of ethanol (EtOH) on survival and progression of three different colon cancer cell lines (HCT116, HT29, and Caco-2). Our data showed that EtOH induces oxidative and endoplasmic reticulum (ER) stress, as demonstrated by reactive oxygen species (ROS) and ER stress markers Grp78, ATF6, PERK and, CHOP increase. Moreover, EtOH triggers an autophagic response which is accompanied by the upregulation of beclin, LC3-II, ATG7, and p62 proteins. The addition of the antioxidant N-acetyl…

Cancer Researchendocrine systemautophagyHO-1Colon cancer cellmedicine.disease_causelcsh:RC254-282ArticleNrf2Downregulation and upregulationSettore BIO/10 - Biochimicamedicinechemistry.chemical_classificationReactive oxygen speciesATF6Endoplasmic reticulumAutophagylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHeme oxygenaseOncologychemistryCancer researchUnfolded protein responseER strecolon cancer cellsethanolMMPsER stressOxidative stressCancers
researchProduct

Heat shock proteins as danger signals for cancer detection

2011

First discovered in 1962, heat shock proteins (HSPs) are highly studied with about 35,500 publications on the subject to date. HSPs are highly conserved, function as molecular chaperones for a large panel of “client” proteins and have strong cytoprotective properties. Induced by many different stress signals, they promote cell survival in adverse conditions. Therefore, their roles have been investigated in several conditions and pathologies where HSPs accumulate, such as in cancer. Among the diverse mammalian HSPs, some members share several features that may qualify them as cancer biomarkers. This review focuses mainly on three inducible HSPs: HSP27, HPS70, and HSP90. Our survey of recent …

Cancer Researchendocrine systemdetectionchemical and pharmacologic phenomenaCancer detectionReview ArticleBioinformaticsdanger signallcsh:RC254-28203 medical and health sciencesstress0302 clinical medicineHsp27Heat shock proteinMedicine030304 developmental biologyCancer0303 health sciencesbiologyHeat shock proteinbusiness.industryCancerhemic and immune systemsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensHsp903. Good healthBiomarker (cell)Oncology030220 oncology & carcinogenesisbiological sciencesbiology.proteinbiomarkerCancer biomarkersbusinessFunction (biology)Frontiers in Oncology
researchProduct

Gene Amplification-Associated Overexpression of the Selenoprotein tRNA Enzyme TRIT1 Confers Sensitivity to Arsenic Trioxide in Small-Cell Lung Cancer

2021

Simple Summary Small-cell lung cancer accounts for approximately 13% of all new lung cancer diagnoses, but in contrast to non-small-cell lung cancer, the implementation of targeted treatments in small-cell lung cancer has been limited, with little improvement in the clinical outcome in the last several decades. Exploring new pathways for targeted therapy, we have observed that extra-copies of the tRNA modifier TRIT1, involved in the translation of selenoproteins, confers sensitivity to arsenic trioxide in small-cell lung cancer. This finding could open a new therapeutic niche for a tumor type with such a dismal clinical course. The alteration of RNA modification patterns is emerging as a co…

Cancer Researchgene amplificationCellTRIT1lcsh:RC254-282Articlechemistry.chemical_compoundRNA modificationsGene duplicationmedicinesmall-cell lung cancerArsenic trioxideGenechemistry.chemical_classificationSelenocysteineChemistryRNAlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenstransfer RNACell biologymedicine.anatomical_structureOncologyTransfer RNAselenoproteinsCàncer de pulmóRNASelenoproteinLung cancer
researchProduct

The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.

2021

The prevalence of primary liver cancer is rapidly rising all around the world. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Unfortunately, the traditional treatment methods to cure HCC showed poor efficacy in patients who are not candidates for liver transplantation. Until recently, tyrosine kinase inhibitors (TKIs) were the front-line treatment for unresectable liver cancer. However, rapidly emerging new data has drastically changed the landscape of HCC treatment. The combination treatment of atezolizumab plus bevacizumab (immunotherapy plus anti-VEGF) was shown to provide superior outcomes and has become the new standard first-line treatment for unresect…

Cancer Researchhepatocellular carcinoma (HCC)clinical trialsOncologyliver cancer (LC)Mini ReviewNeoplasms. Tumors. Oncology. Including cancer and carcinogensimmunotherapyimmune checkpoint blockadeRC254-282Frontiers in oncology
researchProduct

Indocyanine Green to Assess Vascularity of Ileal Conduit Anastomosis During Pelvic Exenteration for Recurrent/Persistent Gynecological Cancer: A Pilo…

2021

IntroductionPelvic exenteration performed for recurrent/persistent gynecological malignancies has been associated with urological short- and long-term morbidity due to altered vascularization of tissues for previous radiotherapy. The aims of the present study were to describe the use of intravenous indocyanine green (ICG) to assess vascularity of urinary diversion (UD) after pelvic exenteration for gynecologic cancers, to evaluate the feasibility and safety of this technique, and to assess the postoperative complications.MethodsProspective, observational, single-center, pilot study including consecutive patients undergoing anterior or total pelvic exenteration due to persistent/recurrent gy…

Cancer Researchmajor postoperative complicationsNeoplasms. Tumors. Oncology. Including cancer and carcinogensanastomosisgynecological canceranastomosimajor postoperative complicationeye diseasespelvic exenteration (PE)body regionsileal conduit diversionSettore MED/40 - GINECOLOGIA E OSTETRICIAOncologyindocyanine green (ICG)anastomosis; gynecological cancer; ileal conduit diversion; indocyanine green (ICG); major postoperative complications; pelvic exenteration (PE)RC254-282Original ResearchFrontiers in Oncology
researchProduct

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

2020

BackgroundWe have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety.MethodsThis randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS.ResultsAt a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 mont…

Cancer Researchmedicine.medical_specialty2435[SDV]Life Sciences [q-bio]ImmunologyMedizinIpilimumabrandomized trialsGastroenterologyAsymptomaticlaw.inventionimmunology03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineClinical endpointImmunology and Allergy1506030212 general & internal medicineAdverse effectRC254-282Clinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryIncidence (epidemiology)MelanomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseimmunology; oncology; randomized trials[SDV] Life Sciences [q-bio]Oncology030220 oncology & carcinogenesisoncologyMolecular Medicinemedicine.symptombusinessBrain metastasismedicine.drug
researchProduct

The Porto European Cancer Research Summit 2021.

2021

Key stakeholders from the cancer research continuum met in May 2021 at the European Cancer Research Summit in Porto to discuss priorities and specific action points required for the successful implementation of the European Cancer Mission and Europe's Beating Cancer Plan (EBCP). Speakers presented a unified view about the need to establish high‐quality, networked infrastructures to decrease cancer incidence, increase the cure rate, improve patient's survival and quality of life, and deal with research and care inequalities across the European Union (EU). These infrastructures, featuring Comprehensive Cancer Centres (CCCs) as key components, will integrate care, prevention and research acros…

Cancer Researchmedicine.medical_specialty:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]infrastructures for translational cancer researchDeclarationTranslational researchContext (language use)comprehensive cancer centresMeeting Reportclinical/prevention trials:profesiones sanitarias::medicina::medicina clínica::medicina de precisión [DISCIPLINAS Y OCUPACIONES]Translational Research Biomedicaloutcomes research:neoplasias [ENFERMEDADES]:Other subheadings::Other subheadings::/prevention & control [Other subheadings]cancer research/care/prevention continuumNeoplasmsPolitical scienceGeneticsmedicineHumansmedia_common.cataloged_instance:Health Occupations::Medicine::Clinical Medicine::Precision Medicine [DISCIPLINES AND OCCUPATIONS]Medicina personalitzadaPrecision MedicineEuropean unionRC254-282media_commongeographySummitgeography.geographical_feature_categoryHealth economics:Natural Science Disciplines::Science::Research::Biomedical Research [DISCIPLINES AND OCCUPATIONS]Neoplasms. Tumors. Oncology. Including cancer and carcinogensGeneral MedicineCancer MissionEuropescience policy:Neoplasms [DISEASES]Medicina - InvestigacióOncologyQuality of LifeCancer researchMolecular MedicineScience policyCàncer - PrevencióOutcomes research:disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica [DISCIPLINAS Y OCUPACIONES]
researchProduct

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Dou…

2021

BackgroundFew data regarding post-induction management following first-line anti-epidermal growth factor receptor (EGFR)-based doublet regimens in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC) are available.MethodsThis multicenter, retrospective study aimed at evaluating clinicians’ attitude, and the safety and effectiveness of post-induction strategies in consecutive patients affected by left-sided RAS/BRAF wild-type mCRC treated with doublet chemotherapy plus anti-EGFR as first-line regimen, who did not experience disease progression within 6 months from induction initiation, at 21 Italian and 1 Spanish Institutions. The measured clinical outcomes were: p…

Cancer Researchmedicine.medical_specialtyColorectal cancerPopulationGastroenterologymaintenanceFOLFIRIFOLFOXInternal medicinecetuximabmedicineAdverse effecteducationRC254-282education.field_of_studybusiness.industryMCRCNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studymedicine.diseaseRegimenFOLFOXOncologyCohortFOLFIRIbusinesspanitumumabmedicine.drugFrontiers in Oncology
researchProduct

SuperHistopath: A Deep Learning Pipeline for Mapping Tumor Heterogeneity on Low-Resolution Whole-Slide Digital Histopathology Images.

2021

High computational cost associated with digital pathology image analysis approaches is a challenge towards their translation in routine pathology clinic. Here, we propose a computationally efficient framework (SuperHistopath), designed to map global context features reflecting the rich tumor morphological heterogeneity. SuperHistopath efficiently combines i) a segmentation approach using the linear iterative clustering (SLIC) superpixels algorithm applied directly on the whole-slide images at low resolution (5x magnification) to adhere to region boundaries and form homogeneous spatial units at tissue-level, followed by ii) classification of superpixels using a convolution neural network (CN…

Cancer Researchmedicine.medical_specialtyComputer scienceMagnificationContext (language use)lcsh:RC254-282Convolutional neural network030218 nuclear medicine & medical imaging03 medical and health sciencesneuroblastoma0302 clinical medicinebreast cancermedicinemelanomatumor region classificationSegmentationCluster analysisOriginal Researchbusiness.industryDeep learningDigital pathologydeep learningPattern recognitionlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmachine learningOncology030220 oncology & carcinogenesisHistopathologyArtificial intelligencebusinessdigital pathologycomputational pathologyFrontiers in oncology
researchProduct